Eli Lilly and Company (NYSE:LLY) Trading 0.3% Higher

Shares of Eli Lilly and Company (NYSE:LLY) traded up 0.3% during trading on Thursday . The company traded as high as $906.79 and last traded at $904.15. 482,598 shares traded hands during trading, a decline of 83% from the average session volume of 2,921,672 shares. The stock had previously closed at $901.26.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on LLY. The Goldman Sachs Group boosted their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Bank of America reiterated a “buy” rating and issued a $1,000.00 price target on shares of Eli Lilly and Company in a research report on Monday. JPMorgan Chase & Co. raised their target price on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a report on Wednesday, May 1st. Finally, Jefferies Financial Group upped their price target on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a report on Monday. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $812.72.

Eli Lilly and Company Price Performance

The stock has a market capitalization of $858.32 billion, a PE ratio of 132.73, a P/E/G ratio of 1.97 and a beta of 0.36. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The stock’s 50-day moving average is $807.55 and its 200 day moving average is $735.35.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.62 earnings per share. As a group, equities analysts predict that Eli Lilly and Company will post 13.76 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 annualized dividend and a yield of 0.58%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the sale, the chief accounting officer now owns 7,130 shares in the company, valued at approximately $5,842,821.10. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 194,978 shares of the business’s stock in a transaction on Monday, June 17th. The shares were sold at an average price of $885.91, for a total value of $172,732,959.98. Following the sale, the insider now owns 97,583,810 shares of the company’s stock, valued at approximately $86,450,473,117.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. Over the last three months, insiders sold 789,704 shares of company stock worth $672,385,964. 0.13% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Lazari Capital Management Inc. bought a new position in shares of Eli Lilly and Company in the first quarter valued at about $233,000. Abich Financial Wealth Management LLC lifted its position in shares of Eli Lilly and Company by 22.7% during the first quarter. Abich Financial Wealth Management LLC now owns 184 shares of the company’s stock worth $143,000 after purchasing an additional 34 shares in the last quarter. TruNorth Capital Management LLC bought a new stake in shares of Eli Lilly and Company during the first quarter valued at approximately $265,000. NBW Capital LLC raised its position in Eli Lilly and Company by 13.3% in the 1st quarter. NBW Capital LLC now owns 876 shares of the company’s stock worth $681,000 after purchasing an additional 103 shares during the last quarter. Finally, Keynote Financial Services LLC acquired a new position in Eli Lilly and Company during the 1st quarter worth $1,564,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.